Claims for Patent: 10,537,580

Summary for Patent: 10,537,580

Title:	Azocane and azonane derivatives and methods of treating hepatitis B infections
Abstract:	Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
Inventor(s):	Hartman; George D. (Lansdale, PA), Kuduk; Scott (Harleysville, PA)
Assignee:	NOVIRA THERAPEUTICS, INC. (Doylestown, PA)
Application Number:	15/848,639
Patent Claims:	1. A method of reducing the viral load associated with an HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of a compound of Formula I: ##STR00241## or a pharmaceutically acceptable salt thereof; wherein R.sup.4 is H or C.sub.1-C.sub.3 alkyl; R.sup.1 is, independently at each occurrence, --OH, halo, --CN, --NO.sub.2, --H.sub.2PO.sub.4, --C.sub.1-C.sub.6 alkyl, --O--C.sub.1-C.sub.6 alkyl, --C.sub.1-C.sub.6 heteroalkyl, --O--C.sub.1-C.sub.6 heteroalkyl, --C.sub.3-C.sub.10 cycloalkyl, --C.sub.3-C.sub.10 heterocycloalkyl, C.sub.6-C.sub.10 aryl, C.sub.5-C.sub.9 heteroaryl, --C.sub.1-C.sub.4 alkyl-(C.sub.3-C.sub.10 cycloalkyl), --C.sub.1-C.sub.4 alkyl-(C.sub.3-C.sub.10 heterocycloalkyl), --C.sub.1-C.sub.4 alkyl-(C.sub.6-C.sub.10 aryl), or --C.sub.1-C.sub.4 alkyl-(C.sub.5-C.sub.9 heteroaryl), wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl groups are optionally substituted 1-5 times with halo, --OH, --CN, or --NO.sub.2; R.sup.2 is, independently at each occurrence, --OH, halo, --CN, --NO.sub.2, R.sup.6, or OR.sup.6, wherein R.sup.6 is, independently at each occurrence, --C.sub.1-C.sub.6 alkyl, --C.sub.1-C.sub.6 heteroalkyl, --C.sub.3-C.sub.10 cycloalkyl, --C.sub.3-C.sub.10 heterocycloalkyl, C.sub.6-C.sub.10 aryl, C.sub.5-C.sub.10 heteroaryl, --C.sub.1-C.sub.4 alkyl-(C.sub.3-C.sub.10 cycloalkyl), --C.sub.1-C.sub.4 alkyl-(C.sub.3-C.sub.10 heterocycloalkyl), --C.sub.1-C.sub.4 alkyl-(C.sub.6-C.sub.10 aryl), or --C.sub.1-C.sub.4 alkyl-(C.sub.5-C.sub.10 heteroaryl), wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl groups are optionally substituted 1-5 times with halo, --OH, --CN, or --NO.sub.2; Cy is ##STR00242## wherein R.sup.11 is, independently at each occurrence, --OH, halo, --CN, --NO.sub.2, --C.sub.1-C.sub.6 alkyl, --O--C.sub.1-C.sub.6 alkyl, --C.sub.1-C.sub.6 heteroalkyl, --O--C.sub.1-C.sub.6 heteroalkyl, --C.sub.3-C.sub.10 cycloalkyl, --C.sub.3-C.sub.10 heterocycloalkyl, C.sub.6-C.sub.10 aryl, C.sub.5-C.sub.9 heteroaryl, --C.sub.1-C.sub.4 alkyl-(C.sub.3-C.sub.10 cycloalkyl), --C.sub.1-C.sub.4 alkyl-(C.sub.3-C.sub.10 heterocycloalkyl), --C.sub.1-C.sub.4 alkyl-(C.sub.6-C.sub.10 aryl), or --C.sub.1-C.sub.4 alkyl-(C.sub.5-C.sub.9 heteroaryl), wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl groups are optionally substituted 1-5 times with halo, --OH, --CN, or --NO.sub.2, or two R.sup.11 groups, together with the carbons to which they are attached, join to form a cyclic phosphate ring; m is 0, 1, 2, 3, or 4; x is 0, 1, 2, 3, 4, or 5; and y is 0, 1, 2, 3, or 4. 2. The method of claim 1, wherein: R.sup.4 is H; m is 0, 1, 2, or 3; x is 0, 1, 2, or 3; and y is 0, 1, 2, or 3. 3. The method of claim 1, wherein: R.sup.1 is, independently at each occurrence, --OH, halo, --CN, --NO.sub.2, --C.sub.1-C.sub.6 alkyl, --O--C.sub.1-C.sub.6 alkyl, --C.sub.1-C.sub.6 heteroalkyl, --O--C.sub.1-C.sub.6 heteroalkyl, --C.sub.3-C.sub.10 cycloalkyl, --C.sub.3-C.sub.10 heterocycloalkyl, --C.sub.1-C.sub.4 alkyl-(C.sub.3-C.sub.10 cycloalkyl), or --C.sub.1-C.sub.4 alkyl-(C.sub.3-C.sub.10 heterocycloalkyl), wherein the alkyl group is optionally substituted 1-5 times with halo or --OH. 4. The method of claim 1, wherein: R.sup.2 is, independently at each occurrence, --OH, halo, --CN, --NO.sub.2, R.sup.6, or OR.sup.6, wherein R.sup.6 is, independently at each occurrence, --C.sub.1-C.sub.6 alkyl, --C.sub.1-C.sub.6 heteroalkyl, --C.sub.3-C.sub.10 cycloalkyl, --C.sub.3-C.sub.10 heterocycloalkyl, --C.sub.1-C.sub.4 alkyl-(C.sub.3-C.sub.10 cycloalkyl), or --C.sub.1-C.sub.4 alkyl-(C.sub.3-C.sub.10 heterocycloalkyl), wherein the alkyl group is optionally substituted 1-5 times with halo or --OH. 5. The method of claim 1, wherein: R.sup.11 is, independently at each occurrence, --OH, halo, --CN, --NO.sub.2, --C.sub.1-C.sub.6 alkyl, --O--C.sub.1-C.sub.6 alkyl, --C.sub.1-C.sub.6 heteroalkyl, --O--C.sub.1-C.sub.6 heteroalkyl, --C.sub.3-C.sub.10 cycloalkyl, --C.sub.3-C.sub.10 heterocycloalkyl, --C.sub.1-C.sub.4 alkyl-(C.sub.3-C.sub.10 cycloalkyl), or --C.sub.1-C.sub.4 alkyl-(C.sub.3-C.sub.10 heterocycloalkyl), wherein the alkyl group is optionally substituted 1-5 times with halo or --OH. 6. The method of claim 1, wherein: R.sup.11 is, independently at each occurrence, --OH, halo, --C.sub.1-C.sub.6 alkyl, --C.sub.1-C.sub.6 heteroalkyl, --C.sub.3-C.sub.10 cycloalkyl, or --C.sub.3-C.sub.10 heterocycloalkyl. 7. The method of claim 1, wherein: R.sup.4 is H; each R.sup.1 is, independently at each occurrence, --OH, halo, --CN, --NO.sub.2, or --C.sub.1-C.sub.6 alkyl; R.sup.2 is selected from --OH, halo, --C.sub.1-C.sub.6 alkyl, --C.sub.1-C.sub.6 heteroalkyl, --C.sub.3-C.sub.10 cycloalkyl, and --C.sub.3-C.sub.10 heterocycloalkyl, wherein the alkyl and cycloalkyl groups are optionally substituted 1-5 times with halo; Cy is ##STR00243## wherein R.sup.11 is, independently at each occurrence, --OH or halo; m is 0, 1 or 2; and x is 0, 1, 2, or 3. 8. The method of claim 1, wherein: R.sup.4 is H; each R.sup.1 is, independently at each occurrence, --OH or halo; R.sup.2 is selected from --OH, halo, and --C.sub.1-C.sub.6 alkyl, wherein the alkyl group is optionally substituted 1-5 times with halo; Cy is ##STR00244## wherein R.sup.11 is, independently at each occurrence, --OH, halo, --C.sub.1-C.sub.6 alkyl, --C.sub.1-C.sub.6 heteroalkyl, --C.sub.3-C.sub.10 cycloalkyl, or --C.sub.3-C.sub.10 heterocycloalkyl; m is 0, 1 or 2; and x is 0, 1, 2, or 3. 9. The method of claim 1, wherein: R.sup.4 is H; each R.sup.1 is, independently at each occurrence, --OH or halo; R.sup.2 is selected from halo and --C.sub.1-C.sub.3 alkyl, wherein the alkyl group is optionally substituted 1-3 times with halo; Cy is ##STR00245## wherein R.sup.11 is, independently at each occurrence, --OH, halo, --C.sub.1-C.sub.3 alkyl, --C.sub.1-C.sub.4 heteroalkyl, --C.sub.3-C.sub.7 cycloalkyl, or --C.sub.3-C.sub.07 heterocycloalkyl; m is 0, 1 or 2; and x is 0, 1, 2, or 3. 10. The method of claim 1, wherein: R.sup.4 is H; each R.sup.1 is, independently at each occurrence, halo; R.sup.2 is selected from halo and --C.sub.1 alkyl, wherein the alkyl group is optionally substituted 1-3 times with halo; Cy is ##STR00246## wherein R.sup.11 is, independently at each occurrence, --OH, halo, --C.sub.1-C.sub.3 alkyl, or --C.sub.3-C.sub.7 cycloalkyl; m is 0, 1 or 2; and x is 2 or 3. 11. The method of claim 1, wherein: R.sup.4 is H; each R.sup.1 is, independently at each occurrence, halo; R.sup.2 is selected from halo and C.sub.1 alkyl, wherein the alkyl group is optionally substituted 1-3 times with halo; Cy is ##STR00247## wherein R.sup.11 is, independently at each occurrence, --OH, halo, --C.sub.1-C.sub.3 alkyl, or --C.sub.3-C.sub.7 cycloalkyl; m is 0, 1 or 2; and x is 2 or 3. 12. The method of claim 11, wherein the compound is selected from: ##STR00248## ##STR00249## 13. The method of claim 1, further comprising administering to the individual at least one additional therapeutic agent selected from the group consisting of a HBV polymerase inhibitor, immunomodulatory agents, pegylated interferon, viral entry inhibitor, viral maturation inhibitor, capsid assembly modulator, reverse transcriptase inhibitor, a cyclophilin/TNF inhibitor, a TLR-agonist, and an HBV vaccine, and a combination thereof. 14. The method of claim 13, wherein the therapeutic agent is a reverse transcriptase inhibitor, and is at least one of Zidovudine, Didanosine, Zalcitabine, 2',3'-dideoxyadenosine, Stavudine, Lamivudine, Abacavir, Emtricitabine, Entecavir, Apricitabine, Atevirapine, ribavirin, acyclovir, famciclovir, valacyclovir, ganciclovir, valganciclovir, Tenofovir, Adefovir, cidofovir, Efavirenz, Nevirapine, Delavirdine, and Etravirine. 15. The method of claim 13, wherein the therapeutic agent is an interferon selected from the group consisting of interferon alpha (IFN-.alpha.), interferon beta (IFN-.beta.), interferon lambda (IFN-.lamda.), and interferon gamma (IFN-.gamma.). 16. The method of claim 15, wherein the interferon is interferon-alpha-2a, interferon-alpha-2b, or interferon-alpha-n1. 17. The method of claim 15, wherein the interferon-alpha-2a or interferon-alpha-2b is pegylated. 18. The method of claim 16, wherein the interferon-alpha-2a is pegylated interferon-alpha-2a (PEGASYS). 19. The method of claim 1, further comprising administering to the individual at least one HBV vaccine, a nucleoside HBV inhibitor, an interferon or any combination thereof. 20. The method of claim 19, wherein the HBV vaccine is selected from the group consisting of RECOMBIVAX HB, ENGERIX-B, ELOVAC B, GENEVAC-B, and SHANVAC B. 21. The method of claim 1, wherein the compound is: ##STR00250##

Details for Patent 10,537,580

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	RECOMBIVAX, RECOMBIVAX HB	hepatitis b vaccine (recombinant)	Injection	101066	07/23/1986		2035-03-19
Glaxosmithkline Biologicals	ENGERIX-B	hepatitis b vaccine (recombinant)	Injection	103239	08/28/1989		2035-03-19
Zr Pharma& Gmbh	PEGASYS	peginterferon alfa-2a	Injection	103964	10/16/2002		2035-03-19
Zr Pharma& Gmbh	PEGASYS	peginterferon alfa-2a	Injection	103964	01/07/2004		2035-03-19